Skip to main content
. 2021 Jul 28;21:866. doi: 10.1186/s12885-021-08596-9

Table 1.

Patient characteristics

Characteristic Training dataset (N = 61) Testing dataset (N = 25) P value External dataset (N = 26)
Age,median (range)years 50(33–74) 51(40–58) 0.970 52(40–74)
FIGO stage, No. (%)
 Ia 18(29.50) 4(16.00) 5(19.23)
 Ib 26(42.60) 10(40.00) 12(46.15)
 IIa 17(27.90) 11(44.00) 9(34.62)
Tumor grade, No. (%) 0.085
 Well differentiate 14(23.00) 6(24.00) 6(23.08)
 Moderately differentiate 29(47.50) 17(68.00) 15(57.69)
 Poorly differentiate 18(29.50) 2(8.00) 5(19.23)
Depth of cervical stromal tumor invasion, No. (%) 0.605
  ≥ 1/2 43(70.50) 19(76.00) 21(80.77)
 <1/2 18(29.50) 6(24.00) 5(19.23)
LVSI, No. (%) 0.921
 Yes 30(49.20) 12(48.00) 15(57.69)
 No 31(50.80) 13(52.00) 11(42.31)
COX-2 expression No. (%) 0.400
 Negative or Weak-Positive 28(45.90) 11(44.00) 11(42.31)
 Moderate-Positive 22(36.10) 12(48.00) 10(38.46)
 Strong-Positive 11(18.00) 2(8.00) 5(19.23)
TNC expression No. (%) 0.975
 Negative or Weak-Positive 40(65.60) 17(68.00) 19 (73.08)
 Moderate-Positive 16(26.20) 6(24.00) 6(23.08)
 Strong-Positive 5(8.20) 2(8.00) 1(3.85)

FIGO International Federation of Gynecology and Obstetrics, LVSI lymphovascular space invasion, COX-2 cyclooxygenase-2, TNC tenascin-C